Verrica Pharmaceuticals

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Verrica Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 2 currently recruiting 6 completed top decile by trial count

Verrica Pharmaceuticals: 9 sponsored US clinical trials, 2 recruiting.

Verrica Pharmaceuticals sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 5 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Common Warts (Verruca Vulgaris), with 1 trials.

Top-decile sponsor footprint

Verrica Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

NCT07457918
RECRUITING Phase 3

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

NCT07246590
NOT YET RECRUITING Phase 3

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

NCT07637734
COMPLETED Phase 2

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

NCT05188729
COMPLETED Phase 2

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

NCT03981822
COMPLETED Phase 2

Cantharidin and Occlusion in Verruca Epithelium

NCT03487549
COMPLETED Phase 3

Cantharidin Application in Molluscum Patients-1

NCT03377790
COMPLETED Phase 3

Cantharidin Application in Molluscum Patients

NCT03377803
COMPLETED Phase 2

Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.

NCT03186378

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 5

Therapeutic Areas

Common Warts (Verruca Vulgaris) 1
Common Warts 1
Human Papilloma Virus (HPV) 1
Warts 1

What is open in the Verrica Pharmaceuticals pipeline

2 recruiting of 9 indexed (22% open); 6 completed (67%).

Phase mix: 5 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Common Warts (Verruca Vulgaris) (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Verrica Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

Verrica Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8101214161820 0%10%20%30%40%50% Total trials Recruiting share Verrica Pharmaceuticals4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyALX OncologyBiosense WebsterEnglewood Hospital and Medical CenterEnsysce Biosciences
Verrica Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Verrica Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Verrica Pharmaceuticals page

9 registered trials is a research-attention snapshot, not an endorsement of Verrica Pharmaceuticals or any single study.

  • 2 of Verrica Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Common Warts (Verruca Vulgaris) is the condition Verrica Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Common Warts (Verruca Vulgaris) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Verrica Pharmaceuticals pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.